| European Case Law Identifier: | ECLI:EP:BA:1993:T022392.19930720 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 20 July 1993 | ||||||||
| Case number: | T 0223/92 | ||||||||
| Application number: | 82305521.5 | ||||||||
| IPC class: | C12N 15/00 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Human immune interferon | ||||||||
| Applicant name: | Genentech, Inc. | ||||||||
| Opponent name: | 1) Roussel Uclaf 2) Biogen Inc. 3) Bioferon biochemische Substanzen GmbH & Co. |
||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Novelty (yes) - Larger protein in the state of the art not unambiguously identified as HIF Inventive step (yes) - Expectation of success not likely by the method known for interferon-Ã Novelty - enabling disclosure - by provision of DNA sequence Late submitted material - admitted - confirmation of previous argument Deposit of a micro-organism - no obligation |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t920223eu1.html
Date retrieved: 17 May 2021